Loading news...
Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) has been assigned an average rating of "Hold" from the twenty-two brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating on the company. The
Shares of Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) traded down 2.6% during mid-day trading on Monday. The company traded as low as $11.01 and last traded at $11.17. 684,941 shares traded hands during trading, a decline of 15% from the average session volume of 807,178 shares. The stock had previously closed at $11.47.
Caxton Associates LLP bought a new stake in Arvinas, Inc. (NASDAQ: ARVN) in the undefined quarter, according to its most recent 13F filing with the SEC. The firm bought 298,062 shares of the company's stock, valued at approximately $2,194,000. Caxton Associates LLP owned 0.41% of Arvinas at the end of the most recent
Shares of Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) have been assigned an average rating of "Hold" from the twenty-three research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody, presented in a poster at the 67th American Society of Hematology (ASH®) Annual Meeting and Exposition, held December 6–9, 2025, in Orlando, Florida.
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York.
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being developed with Pfizer Inc. (NYSE: PFE) as a potential monotherapy for estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting.* Ongoing studies are also evaluating vepdegestrant as a monotherapy and as part of combination therapy for ER+/HER2- breast cancer.
Campbell and CO Investment Adviser LLC acquired a new stake in Arvinas, Inc. (NASDAQ: ARVN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 54,832 shares of the company's stock, valued at approximately $404,000. Campbell and CO Investment Adviser LLC
Arvinas, Inc. ( ARVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - CFO & Treasurer Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Presentation Operator Thank you for standing by, and welcome to Arvinas Third Quarter 2025 Earnings Call. I'd like to remind everyone that this call is being recorded.
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $0.68 per share a year ago.
– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a third party for the commercialization and potential further development of vepdegestrant – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ARV-393, in combination with glofitamab, a CD20xCD3 bispecific antibody, will be presented in a poster presentation at the 2025 American Society of Hematology (ASH) Annual Meeting, being held December 6–9, 2025, in Orlando, Florida.
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences.
NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the third quarter of 2025 and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m.
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer –
NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Arvinas (ARVN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to fulvestrant – NEW HAVEN, Conn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress.
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestrant will be presented at the European Society for Medical Oncology (ESMO) Congress to be held October 17 through 21, 2025, in Berlin, Germany.